Evidence map›Paper›PMID 41799315›Full record

ArticleDepression and anxiety2026

Anxiety and Depressive Symptoms Before and During the COVID-19 Pandemic: A Longitudinal Network Analysis.

Sophie J Blackmore, Marit Sijbrandij, Jose Luis Ayuso-Mateos, Richard Bryant, Matteo Monzio Compagnoni, Katalin Gémes, Erik J Giltay, Almar A L Kok, Vincent Lorant, Roberto Mediavilla and 10 more

Abstract read
In one paragraph

Article in Depression and anxiety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sophie J BlackmoreDepartment of Clinical, Neuro- and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, vu.nl.ORCID https://orcid.org/0009-0002-8811-5437
Marit SijbrandijDepartment of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, vu.nl.
Jose Luis Ayuso-MateosDepartment of Psychiatry, Instituto de Investigación Sanitaria - Hospital Universitario La Princesa, Madrid, Spain, uam.es.
Richard BryantSchool of Psychology, UNSW Sydney, Sydney, Australia, unsw.edu.au.
Matteo Monzio CompagnoniNational Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy, unimib.it.ORCID https://orcid.org/0000-0002-2105-4572
Katalin GémesDivision of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ki.se.
Erik J GiltayDepartment of Psychiatry, Leiden University Medical Center, Leiden, Netherlands, lumc.nl.ORCID https://orcid.org/0000-0001-8874-2292
Almar A L KokDepartment of Psychiatry, Amsterdam UMC Location Vrije Universiteit Amsterdam, Mental Health Programme, Amsterdam Public Health, Amsterdam, Netherlands, vu.nl.
Vincent LorantInstitute of Health and Society (IRSS), Université Catholique de Louvain (UCLouvain), Brussels, Belgium, uclouvain.be.
Roberto MediavillaDepartment of Psychiatry, Instituto de Investigación Sanitaria - Hospital Universitario La Princesa, Madrid, Spain, uam.es.
Josep Maria HaroCentro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain, isciii.es.
Raffael KalischLeibniz Institute for Resilience Research, Mainz, Germany.
Maria MelchiorINSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Epidémiologie Sociale, Santé Mentale et Addictions ESSMA, Sorbonne Université, Paris, 75012, France, sorbonne-universites.fr.
Ellenor Mittendorfer-RutzDivision of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ki.se.
Pablo NicaiseInstitute of Health and Society (IRSS), Université Catholique de Louvain (UCLouvain), Brussels, Belgium, uclouvain.be.
Papoula Petri-RomãoLeibniz Institute for Resilience Research, Mainz, Germany.
Judith van der WaerdenINSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Epidémiologie Sociale, Santé Mentale et Addictions ESSMA, Sorbonne Université, Paris, 75012, France, sorbonne-universites.fr.ORCID https://orcid.org/0000-0002-5324-1372
Henrik WalterDepartment of Psychiatry and Psychotherapy, Charité, Universitätsmedizin, Berlin, Germany.
Anke B WitteveenDepartment of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, vu.nl.
Brenda W J H PenninxDepartment of Psychiatry, Amsterdam University Medical Center, Amsterdam Public Health, Vrije Universiteit, Amsterdam, Netherlands, vu.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the societal impact of the COVID-19 pandemic, research assessing changes in symptoms of anxiety and depression following the sanitary crisis has reported heterogeneous evidence, especially among individuals with pre-existing mental health conditions. Most earlier studies used summary scores of depression or anxiety assessment surveys, which does not provide insights into changes in individual symptoms and symptom structure during the pandemic. Objective: This study used a network analysis to investigate the symptom structure of anxiety and depressive symptoms and temporal changes in symptoms across three timepoints before and during the COVID-19 pandemic in a sample primarily of persons with anxiety and depressive disorders. Methods: Data are retrieved from 675 participants of the Netherlands Study of Depression and Anxiety (NESDA) and Netherlands Study of Depression in Older Persons (NESDO) cohorts who completed all three timepoints. Anxiety and depressive symptoms were assessed using the Beck anxiety inventory (BAI) and the Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR). Symptom networks were estimated for three timepoints: pre-COVID, first COVID-peak (April 2020), second COVID-peak (January/February 2021), and compared. Symptom importance was quantified using centrality indices (strength, betweenness, and closeness), and temporal stability was assessed using the network comparison test (NCT). Results: The symptom networks were largely consistent between the two COVID-19 peak timepoints but differed significantly from the pre-COVID network in terms of global strength. Fear-related anxiety symptoms, sleep-related symptoms, and thoughts of death or suicide demonstrated greater strength centrality at the pre-COVID timepoint compared to both COVID-19 peak timepoints. Conclusion: Our findings illustrate that a stressful situation, such as the COVID-19 pandemic, can result in changes in the complex associations of anxiety and depressive symptoms. Unexpectedly, anxiety symptom networks shifted from being driven by somatic fear responses before the pandemic, toward greater prominence of cognitive appraisal symptoms during the pandemic. Network insights could help focus intervention planning by targeting the key symptoms of anxiety and depression.

Indexed as

AnxietyCOVID-19DepressionDepressive DisorderAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedNetherlands

Identifiers

PMID41799315
PMCPMC12965898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.